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Edited by Varda RotterAbstract ATM and rad3-related protein kinase (ATR), a
member of the phosphoinositide kinase-like protein kinase
family, plays a critical role in cellular responses to DNA
structural abnormalities in conjunction with its interacting
protein, ATRIP. Here, we show that the amino-terminal portion
of ATRIP is relocalized to DNA damage-induced nuclear foci in
an RPA-dependent manner, despite its lack of ability to
associate with ATR. In addition, ATR-free ATRIP protein can
be recruited to the nuclear foci. Our results suggest that the N-
terminal domain of the ATRIP protein contributes to the cell
cycle checkpoint by regulating the intranuclear localization of
ATR.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Nuclear foci1. Introduction
To maintain the integrity of genomic information in or-
ganisms, elaborate devices have been developed that ensure the
ordered progression of cell cycle events. The DNA damage
checkpoint system is one such device; it executes functions that
protect cells from tumorigenesis and death. Recent studies
revealed that this checkpoint is highly conserved from yeasts to
mammals and requires the participation of a family of
checkpoint kinases that share homology with phosphatidylin-
ositol 3-kinase.
In mammals, two structurally related checkpoint kinases,
ATM and ATR, are critical for cellular responses to altered
DNA structures, such as breaks or modiﬁcations [1,2]. It is
believed that ATM and ATR act in parallel pathways that
respond to diﬀerent DNA stresses, including double-strand
breaks (DSBs) and replication blockage [3]. Both proteins
show an aﬃnity for DNA in vitro [4,5] and a signiﬁcant
fraction of each protein is recovered in the chromatin fraction
[6–8]. ATM and ATR are members of a multi-protein complex
that form large nuclear foci when cells are treated with re-* Corresponding author. Fax: +81-562-44-6595.
E-mail address: amatsuur@nils.go.jp (A. Matsuura).
0014-5793/$22.00  2004 Federation of European Biochemical Societies. Pu
doi:10.1016/j.febslet.2004.10.026agents that interfere with DNA synthesis, and are thought to
serve as sensors for DNA damage.
The yeast orthologs of ATR, Rad3 in Schizosaccharomyces
pombe and Mec1 in Saccharomyces cerevisiae, are present as
complexes with the partner proteins Rad26 and Ddc2/Lcd1/
Pie1, respectively [9–12]. ATRIP was isolated as an ATR-as-
sociating protein [13] and is thought to be a mammalian
counterpart of Rad26 and Ddc2. Based on observations that a
mutation in a yeast ATR ortholog led to phenotypes identical
to those produced by a loss of its associating protein, it is
presumed that the two proteins constitute a functional com-
plex [14]. Ddc2 displays DNA binding activity in vitro [15] and
ATRIP is capable of binding to RPA-coated single-stranded
DNA [16], suggesting that these partner proteins assist in re-
cruiting the ATR kinase complex to damaged sites in yeasts. It
has been shown that Rad26 and Ddc2 are required for kinase
activity of the ATR orthologs, both in vivo and in vitro [14,17].
In addition, data have been accumulated that show a potential
role of ATRIP in ATR-mediated phosphorylation of RPA and
MCM [18,19].
In this work, we examine the domains of ATRIP that are
implicated in the action of ATR upon genotoxic stresses. We
show that the amino- and carboxyl-terminal regions con-
tribute separately to intranuclear localization of the ATR–
ATRIP complex. We discuss the roles of two functional
domains of ATRIP involved independently in the ATR-
mediated process.2. Materials and methods
2.1. Antibodies
The following antibodies were used: N-19 (Santa Cruz Biotech) and
ab-2 (Oncogene) for ATR, 9E10 (Babco) and #2272 (Cell Signaling
Technology) for myc, NA13 (Oncogene) for RPA p70, 9H8 (Neo-
Markers) for RPA p34, and ac-15 (Sigma) for b-actin.
To prepare a rabbit polyclonal antibody against the carboxyl ter-
minus of ATRIP (ATRIP-C), the 0.5-kb PvuII–XhoI fragment of
ATRIP cDNA was inserted into the SmaI and XhoI sites of pGEX4T-
2 to yield the pGST-ATRIP-C plasmid. The GST-ATRIP-C fusion
protein, which was puriﬁed from Escherichia coli harboring pGST-
ATRIP-C, was used for immunization. A rabbit polyclonal antibody
against the amino-terminal domain of ATRIP (ATRIP-N) was raised
using the synthetic peptide GTGHPPSKRARGFS, which corresponds
to amino acid residues 25–38 of ATRIP. The antibodies were used
after aﬃnity puriﬁcation.blished by Elsevier B.V. All rights reserved.
Fig. 1. ATRIP associates with ATR through its C-terminal region. (A)
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A retroviral vector derived from the murine leukemia virus pMX-
puro [20] was kindly provided by Prof. T. Kitamura (University of
Tokyo). A BamHI–XhoI fragment of hATRIP full-length cDNA was
inserted into the BamHI–XhoI sites of pMX-puro. To insert carboxyl-
terminal tags into ATRIP, an XhoI site was created immediately before
the termination codon, and a tag sequence from pEF4-mycHis (In-
vitrogen) or pEGFP-c1 (Clontech) was inserted. Retrovirus-based
vectors expressing either the ATRIP N-terminal fragment (1–298
amino acid) containing the coiled-coil domain tagged with the myc
epitope (N32-myc), or the C-terminal fragment without the coiled-coil
domain (198–791 amino acid) tagged with the myc epitope (C64-myc)
were constructed by creating restriction sites using PCR, followed by
insertion of the fragment into the pMX-puro vector.
2.3. Western blotting and immunoprecipitation
For Western blot analysis, 1 106 cells were lysed in 100 ll of al-
kaline extraction buﬀer (0.1 N NaOH, 0.5% 2-mercaptoethanol) at 4
C for 15 min and 1 ml of chilled acetone was added. After storage at
)20 C for 1 h, the cell lysates were centrifuged at 13 000 g for 10
min, and the pellets were washed with 1 ml of chilled acetone and
subjected to SDS–PAGE.
For immunoprecipitation, the cells were lysed in lysis buﬀer [50 mM
Tris–HCl, 150 mM NaCl, 1% Tween 20, 0.3% NP-40, 1 mM NaF, 1
mM Na3VO4, 1 mM PMSF, 0.5 mM cantharidin, and 1 complete
mini (Roche)] at 4 C for 30 min and the supernatant was recovered
after centrifugation at 13 000 g for 30 min. Lysates were incubated
with each antibody at 4 C for 1 h and for an additional 1.5 h with
protein G-Sepharose (Amersham Biosciences). The immunoprecipitate
was washed ﬁve times with wash buﬀer containing 50 mM Tris–HCl,
150 mM NaCl, and 1 mM NaF, and analyzed by SDS–PAGE.
2.4. Immunoﬂuorescence
Immunoﬂuorescence of cells grown on glass coverslips was per-
formed as described previously [21]. Brieﬂy, cells grown on glass
coverslips were washed with PBS, ﬁxed with 4% paraformaldehyde in
PBS for 10 min, and permeabilized with 0.5% Triton X-100 in PBS for
5 min. The coverslips were blocked with 10% FCS in PBS, incubated
with a primary antibody at RT for 1 h, washed with PBS three times,
and incubated with a secondary antibody labeled with AlexaFluor 488
or AlexaFluor 594 (Molecular Probes Inc.). Slides were examined on a
confocal microscope (BX-FLA, Olympus) equipped with epiﬂuores-
cence.
2.5. Small interference RNA
Transfection of dsRNA into HeLa cells was carried out using Oli-
gofectamine (Invitrogen) according to the manufacturer’s instructions.
Small interfering RNA (siRNA) duplexes contained 21 base pairs,
including a 2-deoxynucleotide overhang. For ATRIP, the RNA coding
sequence is 50-GGUCCACAGAUUAUUAGAUdTdT-30 [13], and for
RPA70, it is 50-CACUCUAUCCUCUUUCAUGdTdT-30 [16]. Con-
trol double-stranded siRNA for GFP was purchased from Qiagen. The
cells were analyzed 3–4 days after the ﬁrst transfection.
2.6. Transfection and retroviral infection
Retroviral gene delivery was performed as described previously [21].
Pantropic retroviral packaging was carried out using a pVSV-G
plasmid (Stratagene). Infection frequencies were typically 10–30% for
HeLa cells and 70–90% for A549 cells.Truncated forms of ATRIP. (B) Co-immunoprecipitation of ATR with
truncated ATRIP proteins. A549 cells infected with a control vector or
a retrovirus harboring ATRIP-myc, N32-myc, or C64-myc were col-
lected, and the lysates were analyzed by immunoprecipitation using
anti-ATR or anti-myc antibody. The immunoprecipitates were sub-
jected to Western blot analysis using anti-ATR or anti-myc antibody.
(C) The ATRIP N-terminal fragment does not associate with ATR
after DNA damage. Cells expressing full-length ATRIP-myc or N32-
myc and a control vector were subjected to 10 Gy of X-irradiation or
10 lg/ml aphidicolin. Cell lysates were prepared 1 h after irradiation or
24 h after adding aphidicolin and then immunoprecipitated using anti-
ATR or anti-myc antibody. (D) Eﬀect of the truncated forms of AT-
RIP on the endogenous expression of ATRIP. Lysates of A549 cells
expressing ATRIP-myc, N32-myc, or C64-myc were collected, and the
cell lysates were analyzed with Western blotting using anti-ATRIP-N,
anti-ATRIP-C, anti-ATR, or anti-b-actin antibody.3. Results
3.1. The carboxyl-terminal region of ATRIP contributes to the
interaction with ATR
ATRIP consists of three regions, namely the amino-terminal
region, the coiled-coil domain in the middle, and the carboxyl-
terminal region. To determine which ATRIP domain interacts
with ATR, we expressed a truncated version of the ATRIP
protein using the retroviral promoter. The truncated products,
tagged with the myc epitope, encompassed the amino termi-
nus plus the coiled-coil domain (N32-myc) or the carboxyl
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immunoprecipitated each other reciprocally (Fig. 1B), con-
ﬁrming previous observations that ATR and ATRIP form a
complex [13]. Moreover, we found that C64-myc, but not N32-
myc, retained the ability to interact with ATR (compare lanes
8 and 12 with lanes 7 and 11). We also performed a co-
immunoprecipitation assay to examine whether the association
between ATR and N32-myc changed under conditions inFig. 2. RPA-dependent focus formation of the ATRIP N-terminus with DN
were treated with 10 Gy of X-irradiation or with 10 lg/ml aphidicolin and the
immunostained with anti-ATR, anti-myc, or anti-RPA p34 antibodies. In (C
days the cells were subjected to genotoxic stress. The cells used were (A and C
myc, and (D) A549 with N32-GFP. Dotted circles indicate cells with RPA leve
200 cells harboring anti-myc-stained foci in A and B, or that harboring GFP
cells that lost the RPA signal was calculated. The data are shown as averagwhich ATR–ATRIP was relocated to nuclear foci. As shown
in Fig. 1C, the association between ATR and ATRIP was
unchanged after IR irradiation or aphidicolin treatment;
moreover, N32-myc did not co-immunoprecipitate with ATR
under any conditions tested.
A previous study showed that the amounts of ATR and
ATRIP were regulated interdependently in vivo [13]. We found
that expression of the full-length ATRIP-myc, as well as thatA damage. (A–D) A549 cells expressing truncated versions of ATRIP
n ﬁxed in paraformaldehyde after 1 or 24 h, respectively. The cells were
), the cells were transfected with siRNA against RPA p70 and after 3
) A549 with full-length ATRIP-myc or N32-myc, (B) A549 with C64-
ls that decreased with siRNA. Bar: 10 lm. (E and F) The proportion of
foci in D. With RPA siRNA columns, the proportion of focus-forming
esS.D. of three independent experiments.
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The ﬁnding that the carboxyl-terminal region readily associ-
ates with ATR suggests that the fraction of ATRIP protein
associated with ATR is a determinant of the level of endoge-
nous ATRIP protein.
3.2. The amino terminus of ATRIP contributes to relocalization
to nuclear foci after DNA damage
It has been reported that ATRIP formed nuclear foci to-
gether with ATR after DNA damage [13]. The truncated
ATRIP protein N32-myc was defective in its association with
ATR (Fig. 1B) and consequently it did not show apparent co-
localization with ATR under normal conditions (Fig. 2A).
Interestingly, we found that after DNA damage N32-myc
formed foci eﬃciently, comparable to full-length ATRIP pro-
tein with the carboxyl-terminal myc tag. The foci co-stained
for BRCA1 and endogenous ATR (Fig. 2A and E, and data
not shown). By contrast, the carboxyl-terminal fragment C64-
myc was mainly localized in the nucleus, but was defective in
focus formation (Fig. 2B and E). Since N32-myc did not in-
teract with ATR under any conditions tested (Fig. 1C), this
suggests that the N-terminal region of ATRIP is suﬃcient for
relocalization to nuclear foci and that the relocalization is not
mediated by the direct association with ATR.
3.3. Relocalization of the ATRIP N-terminus to nuclear foci is
RPA-dependent
ATRIP can bind the chromatin via RPA-dependent and -
independent mechanisms [8,16,22]. As previously reported [16],Fig. 3. ATR-independent focus formation of ATRIP. (A and B) Exogenously
or ATRIP without the myc tag was expressed with a retroviral promoter in He
(C) ATRIP forms foci at sites of DNA damage under ATR-repressed cond
siRNA and after 3 days the cells were treated with 10 Gy of X-irradiation o
ATR and anti-myc. Dotted circles indicate cells with ATR levels that decrease
foci. Bar, 10 lm. In (D), the proportion of cells harboring the myc foci waswe observed that RPA and the full-length ATRIP were re-
cruited to the same sites of DNA damages. In addition, co-
localization with RPA was apparent in case of N32-myc
(Fig. 2C). As formation of the ATRIP foci depends on normal
RPA function [16], we examined the possible contribution of
RPA to DNA damage-induced relocation of the ATRIP N-
terminal fragment using the RNA interference technique.
As shown in Fig. 2D and F, the formation of N32-GFP foci
after treatment with aphidicolin or IR was completely abro-
gated in the RPA knockdown cells. This indicates that the
ATRIP N-terminus requires the RPA function to relocalize to
nuclear foci after DNA damage.
3.4. ATRIP can be relocated to nuclear foci in the absence of
ATR
To further analyze ATRIP function independent of ATR,
we used cells that expressed ATRIP from the viral promoter.
The cellular amounts of ATR and ATRIP were co-regulated,
and the siRNA-mediated knockdown of either ATR or AT-
RIP caused a reduction in the amount of the other protein [13].
By contrast, we found comparable amounts of the viral pro-
moter-driven ATRIP, even when the expression of ATR was
eﬀectively repressed (Fig. 3A and B). Therefore, this system
provides the advantage of stable ectopic ATRIP expression in
the ATR-knockdown condition.
When HeLa cells expressing ATRIP-myc were transfected
with ATR siRNA, immunoﬂuorescent signals speciﬁc to ATR
were lost in approximately 70% of the cells within 3 days. In
the ATR knockdown cells, ATRIP-myc protein was expressedexpressed ATRIP is not subject to quantitative regulation. ATRIP-myc
La cells. The cells were analyzed 3 days after ATR siRNA transfection.
itions. HeLa cells expressing ATRIP-myc were transfected with ATR
r with 10 lg/ml aphidicolin. The cells were ﬁxed and stained with anti-
d with siRNA in which exogenously expressed ATRIP-myc still formed
recorded as in Fig. 2.
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Furthermore, even in the absence of ATR, ATRIP formed foci
when cells were treated with 10 lg/ml aphidicolin or 10 Gy IR
(Fig. 3C). These results show that ATRIP alone has the po-
tential to relocalize to nuclear foci after DNA damage. Nev-
ertheless, siRNA-mediated knockdown of ATR reduced the
frequency of ATRIP foci formation signiﬁcantly both after
aphidicolin treatment and after IR irradiation (Fig. 3D).
Therefore, although ATR activity is not required absolutely
for ATRIP focus formation, it may contribute to the stability
of the foci after they are formed.4. Discussion
In this study, we focused on the roles of the associating
protein ATRIP in the stability and dynamic relocation of
ATR. Our results highlight the physiological signiﬁcance of
two functional interfaces of ATRIP: the amino-terminal region
for dynamic relocation of the ATR kinase complex after DNA
damage and the carboxyl-terminal region for interaction with
ATR.
We found that the endogenous expression of ATRIP was
decreased by the ectopic expression of ATRIP. This repression
appears to be achieved post-transcriptionally, since mRNA
levels of endogenous ATRIP were comparable in the ATRIP-
myc-expressing cells (data not shown). As reduction of en-
dogenous ATR has already been shown to decrease endoge-
nous ATRIP in a post-transcriptional mechanism [13], it seems
that one of the most likely explanations of these results is that
ATRIP must bind to ATR to be stable.
Using the RNA interference technique, we demonstrated
that ATR-free ATRIP had the ability to be localized to
damage-induced foci in vivo. A previous study showed that
kinase-negative ATR failed to relocalize to damage-induced
foci [23]. This observation does not necessarily contradict our
results because our study suggests that ATR can contribute
substantially to the eﬃciency of ATRIP focus formation. A
signiﬁcant portion of ATRIP exists free of ATR in cell lysates
[8,18]. Moreover, ATR and ATRIP were easily separated at
high ionic strength [5], and they were in equilibrium between
association and dissociation at physiological ionic strength
[18]. These biochemical characteristics are compatible with a
model in which a fraction of ATRIP is ﬁrst relocalized to foci
to which ATR is subsequently targeted. Alternatively, ATR–
ATRIP might be recruited to sites of damage as a complex and
then partners are exchanged through dissociation-association
events. In either case, the recruited ATR might modify the
biochemical properties of ATRIP (or the ATR–ATRIP com-
plex) or those of other proteins recruited to the sites of dam-
age; this might in turn contribute to the stabilization or
modulation of the protein complex. RPA is one candidate
protein with a function that is modulated by ATR; RPA is
involved in the eﬃcient loading of the ATR–ATRIP complex
to chromatin and is phosphorylated by ATR [16,23]. The hi-
stone H2A variant H2AX is another candidate, as it is phos-
phorylated by ATR and contributes to the accumulation of
ATR at the lesion sites [24,25].We showed that the amino-terminal portion of ATRIP
(N32-myc) was relocalized to DNA damage-induced foci
containing endogenous ATR–ATRIP complex. As no direct
association of the N32-myc fragment with ATR was evident,
we surmise that the amino terminus of ATRIP has the po-
tential to relocate to the multiprotein complex formed at the
site of DNA damage and the recruitment is independent of
ATR. Although ATRIP interacts with RPA and MCM7
[18,19], we could not detect direct interaction between N32-
myc and RPA or MCM7 through a co-immunoprecipitation
experiment (data not shown). Further studies are required to
elucidate the mechanism that directs the N-terminal domain-
mediated recruitment of ATRIP to nuclear foci.
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